Amarantus Subsidiary Elto Pharma
Announces the Issuance of Patents in Singapore and New Zealand
Covering Treatment of Parkinson’s LID
- Patents extend Eltoprazine Parkinson’s disease
LID treatment exclusivity into 2033
San
Francisco, CA -- December 08, 2017 -- InvestorsHub
NewsWire -- Amarantus Bioscience Holdings,
Inc. (OTCPK:
AMBS), a
US-based biotechnology holding company with wholly-owned
subsidiaries developing first-in-class orphan neurologic,
regenerative medicine and ophthalmic therapies, today announced
that its wholly-owned, neurology-focused subsidiary Elto Pharma,
Inc. was granted patents in Singapore and New Zealand covering the
therapeutic use of Eltoprazine for the treatment of motor symptoms
associated with Parkinson’s disease therapies. In New Zealand
Patent No. 702730 was issued, and in Singapore Patent No.
11201408240T was issued. Both patents are titled “Treatment of
Motor Symptoms and Movement Disorder Side Effects Associated with
Parkinson’s disease treatments,” and are valid into
2033.
Elto Pharma is currently redesigning its Phase
2b clinical study for Eltoprazine in the treatment of Parkinson’s
disease Levodopa-induced dyskinesia (PD-LID), targeted to begin
enrollment in 2018. Eltoprazine has received Orphan Drug
Designation from the US FDA for Eltoprazine in the treatment of
PD-LID.
About Amarantus Bioscience Holdings,
Inc.
Amarantus Bioscience Holdings (AMBS) is a
biotechnology company developing treatments and diagnostics for
diseases in the areas of neurology, regenerative medicine and
orphan diseases through its subsidiaries. AMBS’ wholly-owned
subsidiary Elto
Pharma, Inc. has development rights to eltoprazine,
a Phase 2b-ready small molecule indicated for Parkinson's disease
levodopa-induced dyskinesia, Alzheimer’s aggression and adult ADHD.
AMBS acquired the rights to the Engineered Skin Substitute program
(ESS), a regenerative medicine-based approach for treating severe
burns with full-thickness autologous skin grown in tissue culture
that is being pursued by AMBS’ wholly-owned subsidiary
Cutanogen
Corporation. AMBS’ wholly-owned subsidiary MANF
Therapeutics, Inc. owns key intellectual property rights and
licenses from a number of prominent universities related to the
development of the therapeutic protein known as mesencephalic
astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics,
Inc. is developing MANF-based products as
treatments for brain and ophthalmic disorders. MANF was discovered
by the Company’s Chief Scientific Officer John Commissiong, PhD.
Dr. Commissiong discovered MANF from AMBS’ proprietary discovery
engine PhenoGuard. AMBS also owns approximately 80 million shares
of Avant Diagnostics, Inc. via the sale of its wholly-owned
subsidiary Amarantus Diagnostics, Inc. that occurred in May
2016.
For further information please
visit
www.Amarantus.com,
or connect with the Amarantus on Facebook,
LinkedIn, Twitter and Google+.
About Elto Pharma,
Inc.
Eltoprazine is a small molecule 5HT1A/1B
partial agonist in clinical development for the treatment of
Parkinson's disease levodopa-induced dyskinesia (PD-LID),
Alzheimer’s aggression and adult attention deficit hyperactivity
disorder (adult ADHD). Eltoprazine has been evaluated in over 680
human subjects to date, and has a well-established safety profile,
with statistically significant efficacy results across multiple
central nervous system indications.
Eltoprazine was originally developed by Abbott
Pharmaceuticals in aggression-related indications. The eltoprazine
program was out-licensed to PsychoGenics, Inc. (PGI). PGI licensed
eltoprazine to Amarantus in 2014 after a successful
proof-of-concept trial in PD-LID.
In April 2017, Amarantus incorporated the
wholly-owned subsidiary Elto Pharma, Inc. to focus on the clinical
development of Eltoprazine.
Forward-Looking
Statements
Certain statements, other than purely
historical information, including estimates, projections,
statements relating to our business plans, objectives, and expected
operating results, and the assumptions upon which those statements
are based, are forward-looking statements. These forward-looking
statements generally are identified by the words "believes,"
"project," "expects," "anticipates," "estimates," "intends,"
"strategy," "plan," "may," "will," "would," "will be," "will
continue," "will likely result," and similar expressions.
Forward-looking statements are based on current expectations and
assumptions that are subject to risks and uncertainties which may
cause actual results to differ materially from the forward-looking
statements. Our ability to predict results or the actual effect of
future plans or strategies is inherently uncertain. Factors which
could have a material adverse effect on our operations and future
prospects on a consolidated basis include, but are not limited to:
changes in economic conditions, legislative/regulatory changes,
availability of capital, interest rates, competition, and generally
accepted accounting principles. These risks and uncertainties
should also be considered in evaluating forward-looking statements
and undue reliance should not be placed on such
statements.
Amarantus Investor and Media
Contact:
Ascendant Partners, LLC
Richard Galterio
+1-732-410-9810
rich@ascendantpartnersllc.com
Source: Amarantus Bioscience Holdings,
Inc.